{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Participants who experienced an SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Participants who experienced a TRC105 related SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 4.03)","groups":[{"description":"All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.\n\nTRC105: Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.\n\nBevacizumab: Bevacizumab will be dosed every two weeks.","id":"OG000","title":"TRC105 and/or Bevacizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"20 months","title":"Frequency and Severity of Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}